

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	SAHIN et al.	
Serial No.:	To be assigned	Art Unit: not yet assigned
Filed:	Concurrently herewith	Examiner: not yet assigned
Entitled:	GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND THE USE THEREOF	

US national phase of PCT/EP2003/013091 filed November 21, 2003 and designating the US
Attorney Docket No.: GMD-102.1P US

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants submit this Information Disclosure Statement pursuant to 37 C.F.R. §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A modified Form PTO-1449 listing the cited documents is also enclosed, as well as, for the Examiner's convenience, paper copies of the non-patent documents. In regards to the cited U.S Patent and Foreign Patent documents, as stated as permissible in MPEP, Chapter 609, paper copies of only the pages of the applicable portions that caused the document to be listed in the International Search Report conducted by the ISA/EPO are enclosed. An extra copy of the English version of the ISR is also included for the Examiner's convenience. Pursuant to 37 C.F.R. § 1.97(b)(3), no fee is believed to be required with this submission.

U.S. Patents:

U.S. Pat. No. 6,235,481 B1 issued May 22, 2001 (Horikawa et al.), enclosed paper copy of cover page and page for Column 79, lines 47-67, Column 80, Example 5, lines 15-67;

Foreign Patent Documents:

WO 99/64452 A1 published December 16, 1999 (Elshourbagy, N.), enclosed paper copy of entire document as cited in ISR;

WO 01/027257 A1 published April 19, 2001 (O'Brien et al.), enclosed paper copy of entire document as cited in ISR;

WO 01/062920 A2 published August 30, 2001 (Cheever et al.), enclosed paper copy of entire document as cited in ISR;

WO 01/075067 A2 published October 11, 2001 (Drmanac et al.); enclosed paper copy of cover page disclosing abstract as cited in ISR and pages 100 to 103 disclosing all claims;

WO 02/014500 A2 published February 21, 2002 (Escobedo et al.), enclosed paper copy of cover page disclosing abstract and pages 267,409,486,505,614,646,661,680,684 as cited in ISR, and pages 880 to 882 disclosing all claims;

WO 02/061087 A2 published August 8, 2002 (Burmer et al.), enclosed paper copy of cover page and page 33 disclosing paragraph 129 as cited in ISR;

WO 02/103028 A2 published December 27, 2002 (Baranova et al.), enclosed cover page and page 41 as cited in ISR;

Other Documents:

Baranova et al., *FEBS Letters*, 508:143-148 (2001), paper copy of entire document enclosed;

Engberg et al., *Immunotechnology*, 4:273-278 (1999), paper copy of entire document enclosed;

Koslowski et al., *Cancer Research*, 62:6750-6755 (2002), paper copy of entire document enclosed;

O'Dowd et al., *Genomics*, 47:310-313 (1998), paper copy of entire document enclosed;


Reiter et al., *Proc. Natl. Acad. Sci. USA*, 94:4631-4636 (1997), paper copy of entire document enclosed.

Applicants do not intend to represent that any of the documents submitted herein is material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

U.S. Appln. No. [to be assigned]
Atty. Docket: GMD-102.1P US

Applicants respectfully request that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,



Leon R. Yankwich, Reg. No. 30,237
Michael R. Wesolowski, Reg. No. 50,944
Attorneys for Applicants
YANKWICH & ASSOCIATES, P.C.
201 Broadway
Cambridge, Massachusetts 02139
telephone: (617) 374-3700
telefax: (617) 374-0055


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

The undersigned hereby certifies that this correspondence and accompanying enclosures are being deposited with the U.S. Postal Service "Express Mail Post Office to Address" Service under 37 CFR § 1.10, postage prepaid, in an envelope addressed to: **Mail Stop PCT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

Express Mailing Label No.: EV 509622125 US

May 20, 2005

date



Nasim G. Memon

Modified FORM PTO-1449	ATTY. DOCKET NO. GMD-102.1P US	SERIAL NO. To be assigned
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT SAHIN et al.	
(Use several sheets if necessary)	FILING DATE concurrently herewith	GROUP To be assigned

REFERENCE DESIGNATION		U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	U.S. 6,235,481 B1	05/22/01	Horikawa et al.	435	6	10/21/99
	AB						
	AC						

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TRANSLATION YES NO
	BA	WO 99/64452 A1	12/16/99	Elshourbagy N.	C07K	14/435	
	BB	WO 01/027257 A1	04/19/01	O'Brien et al.	C12N	15/00	
	BC	WO 01/062920 A2	08/30/01	Cheever et al.	C12N	15/12	
	BD	WO 01/075067 A2	10/11/01	Drmanac et al.	C12N	15/??	
	BE	WO 02/014500 A2	02/21/02	Escobedo et al.	C12N	15/00	
	BF	WO 02/061087 A2	08/08/02	Burmer et al.	C12N	15/12	
	BG	WO 02/103028 A2	12/27/02	Baranova et al.	C12Q	??/??	
	BH						
	BI						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	CA Baranova et al., "In Silico Screening for Tumour-Specific Expressed Sequences in Human Genome", FEBS Letters, 508:143-148 (2001)
	CB Engberg et al., "Recombinant antibodies with the antigen-specific MHC restricted specificity of T cells: Novel Reagents for Basic and Clinical Investigations and Immunotherapy", Immunotechnology, 4:273-278 (1999)
	CC Koslowski et al., "Multiple Splice Variants of Lactate Dehydrogenase C Selectively Expressed in Human Cancer", Cancer Research, 62:6750-6755 (2002)
	CD O'Dowd et al., "Discovery of Three Novel G-Protein-Coupled Receptor Genes", Genomics, 47:310-313 (1998)
	CE Reiter et al., "Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to Major Histocompatibility Complex/Peptide Class I Complexes with T Cell Receptor-like Specificity", Proc. Natl. Acad. Sci. USA, 94:4631-4636 (1997)
	CF
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.